Literature DB >> 22713868

Mutant p53: one name, many proteins.

William A Freed-Pastor1, Carol Prives.   

Abstract

There is now strong evidence that mutation not only abrogates p53 tumor-suppressive functions, but in some instances can also endow mutant proteins with novel activities. Such neomorphic p53 proteins are capable of dramatically altering tumor cell behavior, primarily through their interactions with other cellular proteins and regulation of cancer cell transcriptional programs. Different missense mutations in p53 may confer unique activities and thereby offer insight into the mutagenic events that drive tumor progression. Here we review mechanisms by which mutant p53 exerts its cellular effects, with a particular focus on the burgeoning mutant p53 transcriptome, and discuss the biological and clinical consequences of mutant p53 gain of function.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22713868      PMCID: PMC3387655          DOI: 10.1101/gad.190678.112

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  203 in total

Review 1.  Mutant p53 gain-of-function in cancer.

Authors:  Moshe Oren; Varda Rotter
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-02       Impact factor: 10.005

2.  Modulation of the vitamin D3 response by cancer-associated mutant p53.

Authors:  Perry Stambolsky; Yuval Tabach; Giulia Fontemaggi; Lilach Weisz; Revital Maor-Aloni; Zehava Siegfried; Zahava Sigfried; Idit Shiff; Ira Kogan; Moshe Shay; Eyal Kalo; Giovanni Blandino; Itamar Simon; Moshe Oren; Varda Rotter
Journal:  Cancer Cell       Date:  2010-03-16       Impact factor: 31.743

3.  p53 Regulates the Ras circuit to inhibit the expression of a cancer-related gene signature by various molecular pathways.

Authors:  Yosef Buganim; Hilla Solomon; Yoach Rais; Daria Kistner; Ido Nachmany; Mariana Brait; Shalom Madar; Ido Goldstein; Eyal Kalo; Nitzan Adam; Maya Gordin; Noa Rivlin; Ira Kogan; Ran Brosh; Galit Sefadia-Elad; Naomi Goldfinger; David Sidransky; Yoel Kloog; Varda Rotter
Journal:  Cancer Res       Date:  2010-03-02       Impact factor: 12.701

Review 4.  The first 30 years of p53: growing ever more complex.

Authors:  Arnold J Levine; Moshe Oren
Journal:  Nat Rev Cancer       Date:  2009-10       Impact factor: 60.716

Review 5.  20 years studying p53 functions in genetically engineered mice.

Authors:  Lawrence A Donehower; Guillermina Lozano
Journal:  Nat Rev Cancer       Date:  2009-09-24       Impact factor: 60.716

Review 6.  p53 and E2f: partners in life and death.

Authors:  Shirley Polager; Doron Ginsberg
Journal:  Nat Rev Cancer       Date:  2009-10       Impact factor: 60.716

Review 7.  Mdm2-mediated ubiquitylation: p53 and beyond.

Authors:  J-C Marine; G Lozano
Journal:  Cell Death Differ       Date:  2010-01       Impact factor: 15.828

8.  The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis.

Authors:  Giulia Fontemaggi; Stefania Dell'Orso; Daniela Trisciuoglio; Tal Shay; Elisa Melucci; Francesco Fazi; Irene Terrenato; Marcella Mottolese; Paola Muti; Eytan Domany; Donatella Del Bufalo; Sabrina Strano; Giovanni Blandino
Journal:  Nat Struct Mol Biol       Date:  2009-09-27       Impact factor: 15.369

Review 9.  p53 and metabolism.

Authors:  Karen H Vousden; Kevin M Ryan
Journal:  Nat Rev Cancer       Date:  2009-09-17       Impact factor: 60.716

10.  Mutant p53 drives invasion by promoting integrin recycling.

Authors:  Patricia A J Muller; Patrick T Caswell; Brendan Doyle; Marcin P Iwanicki; Ee H Tan; Saadia Karim; Natalia Lukashchuk; David A Gillespie; Robert L Ludwig; Pauline Gosselin; Anne Cromer; Joan S Brugge; Owen J Sansom; Jim C Norman; Karen H Vousden
Journal:  Cell       Date:  2009-12-24       Impact factor: 41.582

View more
  537 in total

Review 1.  The DNA damage-induced cell death response: a roadmap to kill cancer cells.

Authors:  Sonja Matt; Thomas G Hofmann
Journal:  Cell Mol Life Sci       Date:  2016-01-20       Impact factor: 9.261

2.  p53 reactivation with induction of massive apoptosis-1 (PRIMA-1) inhibits amyloid aggregation of mutant p53 in cancer cells.

Authors:  Luciana P Rangel; Giulia D S Ferretti; Caroline L Costa; Sarah M M V Andrade; Renato S Carvalho; Danielly C F Costa; Jerson L Silva
Journal:  J Biol Chem       Date:  2019-01-02       Impact factor: 5.157

3.  Significant expression of CHK1 and p53 in bladder urothelial carcinoma as potential therapeutic targets and prognosis.

Authors:  Linfeng Zheng; Yuping Zhu; Lei Lei; Wenyong Sun; Guoping Cheng; Shifeng Yang
Journal:  Oncol Lett       Date:  2017-11-03       Impact factor: 2.967

Review 4.  Regulation of pyruvate metabolism in metabolic-related diseases.

Authors:  Nam Ho Jeoung; Chris R Harris; Robert A Harris
Journal:  Rev Endocr Metab Disord       Date:  2014-03       Impact factor: 6.514

5.  p53 oligomerization status modulates cell fate decisions between growth, arrest and apoptosis.

Authors:  Nicholas W Fischer; Aaron Prodeus; David Malkin; Jean Gariépy
Journal:  Cell Cycle       Date:  2016-10-18       Impact factor: 4.534

6.  Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers.

Authors:  Pradeep Chaluvally-Raghavan; Fan Zhang; Sunila Pradeep; Mark P Hamilton; Xi Zhao; Rajesha Rupaimoole; Tyler Moss; Yiling Lu; Shuangxing Yu; Chad V Pecot; Miriam R Aure; Sylvain Peuget; Cristian Rodriguez-Aguayo; Hee-Dong Han; Dong Zhang; Avinashnarayan Venkatanarayan; Marit Krohn; Vessela N Kristensen; Mihai Gagea; Prahlad Ram; Wenbin Liu; Gabriel Lopez-Berestein; Philip L Lorenzi; Anne-Lise Børresen-Dale; Koei Chin; Joe Gray; Nelson J Dusetti; Sean E McGuire; Elsa R Flores; Anil K Sood; Gordon B Mills
Journal:  Cancer Cell       Date:  2014-12-08       Impact factor: 31.743

7.  Partial p53-dependence of anisomycin-induced apoptosis in PC12 cells.

Authors:  R Schipp; J Varga; J Bátor; M Vecsernyés; Z Árvai; M Pap; József Szeberényi
Journal:  Mol Cell Biochem       Date:  2017-04-21       Impact factor: 3.396

8.  Mutant p53 perturbs DNA replication checkpoint control through TopBP1 and Treslin.

Authors:  Kang Liu; Fang-Tsyr Lin; Joshua D Graves; Yu-Ju Lee; Weei-Chin Lin
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-24       Impact factor: 11.205

9.  Rapid 3D phenotypic analysis of neurons and organoids using data-driven cell segmentation-free machine learning.

Authors:  Philipp Mergenthaler; Santosh Hariharan; James M Pemberton; Corey Lourenco; Linda Z Penn; David W Andrews
Journal:  PLoS Comput Biol       Date:  2021-02-22       Impact factor: 4.475

10.  The activating transcription factor 3 protein suppresses the oncogenic function of mutant p53 proteins.

Authors:  Saisai Wei; Hongbo Wang; Chunwan Lu; Sarah Malmut; Jianqiao Zhang; Shumei Ren; Guohua Yu; Wei Wang; Dale D Tang; Chunhong Yan
Journal:  J Biol Chem       Date:  2014-02-19       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.